Phase 1 Pancreatic Cancer Trial, Recruiting NCT04678648 Sponsor: RasCal Therapeutics, Inc. Condition: Pancreatic Cancer
Back to Pancreatic Cancer

Phase 1 Pancreatic Cancer Trial, Recruiting

NCT04678648
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with an advanced or spreading cancer that has either stopped responding to existing treatments, has continued to grow despite standard treatment, or where existing treatments have caused intolerable side effects.
  • People whose cancer has tumors that can be measured or evaluated through standard imaging or laboratory tests.
  • People who have an adequate level of physical functioning, as measured by a standard medical scale called the ECOG performance status (confirm with trial site for the specific score required).
  • People who are 18 years of age or older.
  • People whose cancer either has a specific genetic change called a RAS mutation (regardless of cancer type), or who have a type of brain cancer called glioblastoma (with or without a RAS mutation).

Who may not be able to join:

  • People who are currently receiving cancer treatment at the time of enrolling in the trial.
  • People who have a clinically significant disease or condition affecting a major organ system.
  • People who have significant heart or cardiovascular disease, or certain abnormalities on a heart tracing test (ECG).
  • People with a known condition called Gilbert's disease, which affects how the liver processes certain substances.
  • People who have had a separate, different cancer within the past two years, or who currently have another cancer alongside the target cancer.
  • People who experience recurring episodes of low potassium levels in the blood.
  • People who are already experiencing nausea, vomiting, or diarrhea at a certain level of severity before the trial begins.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Michael Mann, MD, RasCal Therapeutics, Inc.

Phone: 310-498-7171

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
RasCal Therapeutics, Inc.
Registry
ClinicalTrials.gov
Start date
3 March 2021
Est. completion
15 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Maximum Tolerated Dose (MTD) for RSC-1255 as monotherapy; Recommended Phase 2 Dose (RP2D) for RSC-1255 as monotherapy

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov